From complexity to clarity in cell and gene therapy
Breakthrough CGT therapies are coming thick and fast, now pharma must work on multiple fronts to educate non-specialist stakeholders about their exciting possibilities
Close log in window
The Astellas head of medical affairs follows up with answers to questions during her virtual keynote earlier this year
View the results of a survey of over 1000 pharma executives on the impact COVID-19 has had and will have on their operations
The mega congresses of the past look likely to make way for more virtual, focused and, probably, hybrid physical/digital events
If pharma wants patients and patient groups capable of working with it at every stage of the drug development process it must listen to, and...
